Home/Themes/GLP-1 Stocks

GLP-1 Stocks

HealthcareInnovationGrowth

Commercial GLP-1 leaders, next-generation metabolic drug developers, diabetes devices, and digital health platforms. The universe is dominated by GLP-1 Leaders (60%) and Devices & Adjacencies (19%), underperforming SPY by 10.2 percentage points YTD.

YTD Return

-0.8%

-10.2 pts vs SPY

7 of 23 beat SPY

1-Month Return

+11.0%

+9.9 pts vs SPY

Universe Size

23 Stocks

Curated theme basket

Market Cap

$3.02T

Total capitalization

Theme Performance

GLP-1 Stocks Performance vs SPY and QQQ

Track GLP-1 Stocks without checking every day

Weekly updates on performance, valuation changes, and key movers.

Theme Composition

GLP-1 Stocks Breakdown

Composition last reviewed

As of Jun 1, 2026

Categories reflect each company's primary theme role. Some companies may have exposure to multiple segments.

Theme Overview

GLP-1 Stocks Overview

A summary of how the theme breaks down across business segments and where concentration risk lives.

Selected Stocks

22

in theme

Total Market Cap

$2.8T

combined

Highly Concentrated

The top 2 segments (GLP-1 Leaders & Devices & Adjacencies & Tools & AI Discovery & Other segments) represent 85.9% of this theme by market cap.

Top GLP-1 Stocks Stocks

Top GLP-1 Stocks Stocks by Segment, Performance, and Valuation

LLY

Eli Lilly and Company

#1

Price$1,235.56

Mkt Cap-

YTD+14.4%

Rev G47.4%

MRK

Merck & Co., Inc.

#2

Price$128.86

Mkt Cap-

YTD+21.1%

Rev G2.5%

AMGN

Amgen Inc.

#3

Price$368.10

Mkt Cap-

YTD+12.3%

Rev G9.1%

TMO

Thermo Fisher Scientific Inc.

#4

Price$516.62

Mkt Cap-

YTD-12.8%

Rev G5.4%

ABT

Abbott Laboratories

#5

Price$95.84

Mkt Cap-

YTD-22.8%

Rev G6.6%

ISRG

Intuitive Surgical, Inc.

#6

Price$427.30

Mkt Cap-

YTD-24%

Rev G21.4%

DHR

Danaher Corporation

#7

Price$194.19

Mkt Cap-

YTD-15.7%

Rev G4%

PFE

Pfizer Inc.

#8

Price$24.07

Mkt Cap-

YTD-4.4%

Rev G1.4%

SYK

Stryker Corporation

#9

Price$313.38

Mkt Cap-

YTD-10%

Rev G8.8%

MDT

Medtronic plc

#10

Price$83.83

Mkt Cap-

YTD-12.7%

Rev G8.4%

#								Chart (YTD)
1	LLY Eli Lilly and Company	$1,235.56	$1.17T	+14.4%	+7.5%	53.8	47.4%
2	MRK Merck & Co., Inc.	$128.86	$318.26B	+21.1%	+7.8%	17.7	2.5%
3	AMGN Amgen Inc.	$368.10	$198.66B	+12.3%	+6.5%	25.9	9.1%
4	TMO Thermo Fisher Scientific Inc.	$516.62	$191.99B	-12.8%	+10%	29.1	5.4%
5	ABT Abbott Laboratories	$95.84	$166.94B	-22.8%	+5.9%	25.8	6.6%
6	ISRG Intuitive Surgical, Inc.	$427.30	$151.33B	-24%	+2.1%	54.3	21.4%
7	DHR Danaher Corporation	$194.19	$137.44B	-15.7%	+5.8%	38.5	4%
8	PFE Pfizer Inc.	$24.07	$136.92B	-4.4%	-6%	17.7	1.4%
9	SYK Stryker Corporation	$313.38	$120.14B	-10%	+3.9%	37.3	8.8%
10	MDT Medtronic plc	$83.83	$107.63B	-12.7%	+3.9%	22.5	8.4%

Showing 10 of 22 stocks

View all 22 stocks

Daily Intelligence

Yesterday in GLP-1 Stocks

Key headlines and stock-level catalysts from the last trading session.

Last session recap is current.

End-of-day analysis published after market close. Next update after Jul 8, 2026 market close.

Session Brief

Jul 7, 2026

NEUTRAL

The latest EOD theme brief is not available yet. The most recent stock-level drivers are shown below.

Key Drivers

Stock-Level Catalysts

Sentiment reflects catalyst narrative, not price direction - a stock can close lower while the fundamental driver is bullish.

PFENEUTRAL

Pfizer Inc.

+1.48%

last session

Fresh EOD news and price action made this stock a theme driver.

Sourcezacks.com - Jul 6

ISRGNEUTRAL

Intuitive Surgical, Inc.

-1.28%

last session

Fresh EOD news and price action made this stock a theme driver.

Sourcezacks.com - Jul 6

LLYNEUTRAL

Eli Lilly and Company

+2.96%

last session

Fresh EOD news and price action made this stock a theme driver.

Sourcezacks.com - Jul 6

ABTNEUTRAL

Abbott Laboratories

+0.22%

last session

Fresh EOD news and price action made this stock a theme driver.

Sourcezacks.com - Jul 6

AMGNNEUTRAL

Amgen Inc.

+0.45%

last session

Fresh EOD news and price action made this stock a theme driver.

Sourcezacks.com - Jul 6

Updated after market close

Jul 7, 2026

Valuation Pulse

Are GLP-1 Stocks cheap or expensive right now?

DCF valuations and Wall Street ratings across the theme.

Data as of Jul 8, 2026 (EOD)

22 stocks in theme - 16 with full coverage

DCF Valuation

(Intrinsic Value)

Median Upside +3%

16

of 22

covered

Undervalued

6(38%)

Fair Value

3(19%)

Overvalued

7(44%)

Top DCF Upside (Undervalued Only)

PFE

Pfizer Inc.

ABT

Abbott Laboratories

AMGN

Amgen Inc.

Wall Street Consensus

(Price Targets)

Median Target Upside +17%

22

of 22

covered

Buy / Strong Buy

18(82%)

Hold

4(18%)

Sell / Strong Sell

0(0%)

Coverage Snapshot

Consensus is based on 22 stocks with analyst price targets. DCF analysis is based on 16 stocks with intrinsic value estimates.

Valuation Distribution

(22 covered stocks)

Theme Valuation Score

2.0

Cheap

Scale: 1 (Cheap) to 5 (Expensive)

1

Bargain

8 stocks (36%)

>= +30%

2

Cheap

8 stocks (36%)

+10% to +30%

3

Fair

5 stocks (23%)

-10% to +10%

4

Expensive

0 stocks (0%)

-25% to -10%

5

Very Expensive

1 stocks (5%)

<= -25%

Valuation score blends Wall Street target upside at 65% weight and DCF upside at 35% weight when both are available; single-source covered stocks use the available signal. Higher score means more expensive.

Earnings Calendar

Upcoming Earnings in GLP-1 Theme

Companies reporting in the next 30 days. Earnings dates and estimates can change as reports approach.

View Full Calendar

Company	Reports	Timing	Est. EPS	Est. Revenue
ABTAbbott Laboratories	Thu, Jul 16	Unconfirmed	$1.28 est.	$12.54B est.
TMOThermo Fisher Scientific Inc.	Wed, Jul 22	Unconfirmed	$5.75 est.	$11.71B est.
ISRGIntuitive Surgical, Inc.	Tue, Jul 28	Unconfirmed	$2.48 est.	$2.82B est.
DHRDanaher Corporation	Tue, Jul 28	Unconfirmed	$1.85 est.	$6.09B est.
DXCMDexCom, Inc.	Wed, Jul 29	Unconfirmed	$0.60 est.	$1.29B est.
VKTXViking Therapeutics, Inc.	Wed, Jul 29	Unconfirmed	-$1.21 est.	-
SYKStryker Corporation	Thu, Jul 30	Unconfirmed	$3.49 est.	$6.58B est.
WWWW International, Inc.	Thu, Jul 30	Unconfirmed	$0.48 est.	$159M est.

and 10 more in the next 30 days.

Estimates are based on available consensus data. BMO = Before Market Open, AMC = After Market Close.

Research & Methodology

How to evaluate GLP-1 Stocks

Methodology, investment thesis, and key risks for this theme.

Show Details

How we evaluate these stocks

Our methodology

We separate commercial GLP-1 leaders, pipeline challengers, suppliers, devices, and healthcare platforms. The analysis weighs prescription growth, clinical data, capacity, reimbursement, and valuation.

Direct obesity or metabolic exposure must be material
Commercial leaders are separated from pipeline-stage names
Trial data and safety profile drive challenger value
Manufacturing capacity and reimbursement matter
Valuation is checked against product durability

See full stock table

Investment thesis

Why this theme exists

GLP-1 drugs are reshaping obesity, diabetes, and cardiometabolic care. The opportunity spans large pharma leaders, differentiated pipeline assets, manufacturing capacity, and adjacent healthcare models.

Obesity treatment is a large and underpenetrated market
Commercial leaders can scale multi-billion-dollar franchises
Next-generation drugs compete on efficacy, dosing, and tolerability
Manufacturing capacity can become a competitive advantage
Adjacencies may benefit or face demand disruption

Read performance

Key risks

What could go wrong

The market is large, but investment outcomes depend on safety, trial results, pricing, reimbursement, supply, and patent protection. Smaller challengers can move sharply on single catalysts.

Clinical failures or safety issues can reset valuations
Insurance coverage can limit market size
Manufacturing constraints can cap revenue growth
Competition can pressure pricing and share
Pipeline-stage companies may need financing before approval

Check valuation pulse

FAQ

Frequently asked questions

Common questions investors have about the GLP-1 Stocks theme.

01What are GLP-1 stocks?

GLP-1 stocks are companies involved in obesity, diabetes, or metabolic treatments using GLP-1 or related mechanisms, plus selected healthcare companies affected by obesity treatment demand.

02Which companies are the direct GLP-1 leaders?

The direct commercial leaders are the large pharmaceutical companies with marketed obesity or diabetes drugs and the manufacturing capacity to scale them. Pipeline-stage biotechs are higher-risk challengers rather than proven leaders.

03Are obesity biotech stocks risky?

Yes. Smaller pipeline companies can move sharply on trial results, safety data, financing, and regulatory updates.

04How is this different from biotech healthcare stocks?

The healthcare theme is broad. This page focuses specifically on obesity, GLP-1, metabolic health, and related second-order exposures.

05What should I compare first?

Start with market cap, revenue growth, profitability, return history, and valuation, then separate commercial products from pipeline-stage risk. For biotechs, trial data and cash runway matter heavily.

Related Themes

Continue from GLP-1 Stocks into adjacent themes

Curated theme paths that share catalysts, supply chains, or investor workflows with this page.

View all themes

Biotech & Healthcare Stocks

US biotech and healthcare stocks screened by market data, analyst coverage, and pipeline depth — large-cap pharma, gene therapy, medical devices, and AI-driven drug discovery.

vs SPY: +0.1 pts

AI Stocks

Track US AI stocks with daily updated market data, an equal-weight theme performance chart, valuation metrics, performance tracking, and a research-first stock table.

vs SPY: +0.2 pts

Robotics & Automation Stocks

Robotics and automation stocks screened across industrial automation, surgical robots, warehouse systems, and AI-driven autonomous platforms with daily updated market data.

vs SPY: +0.1 pts

Ready to screen these stocks?

Open the full screener pre-loaded with this theme's filters to sort, rank, and compare.

Open the Screener Explore All Themes

Updated daily•Free•No signup